Novo Nordisk lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back sales of its branded treatments.The Danish company’s sales have been hit by alternative compounded versions of its Ozempic and Wegovy drugs,

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast amid weaker sales of its blockbuster Wegovy weight loss drugs. Sales of the company's popular Wegovy obesity drug hit 17.

Obesity drugmaker Novo Nordisk on Wednesday cut its full-year sales and profit outlook amid lacklustre U.S. prescription data and posted first-quarter operating profit above analyst forecasts.